Research Article
Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients
Table 3
Adverse events and outcomes.
| | Variable | Dexamethasone (n = 83) | Usual care (n = 137) | value |
| | Bleeding, n (%) | 22 (27) | 16 (12) | 0.005 | | Nonventricular arrhythmia, n (%) | 26 (31) | 26 (19) | 0.037 | | Ventricular arrhythmia, n (%) | 1 (1) | 4 (3) | 0.408 | | Clostridioides difficile infection, n (%) | 5 (6) | 5 (4) | 0.412 | | Thromboembolic events, n (%) | 17 (20) | 24 (18) | 0.584 | | Hyperglycemia, n (%) | 33 (40) | 32 (23) | 0.010 | | Bacterial infection, n (%) | 59 (71) | 84 (61) | 0.141 | | Septic shock, n (%) | 39 (47) | 44 (32) | 0.027 | | Initial ICU stay, days, median (IQR) | 11 (4–21) | 5 (2–14) | <0.001 | | ICU readmission, n (%) | 5 (6) | 12 (9) | 0.476 | | Total ICU stay, days, median (IQR) | 11 (4–22) | 5 (2–15) | 0.001 | | Length of hospital stay, days, median (IQR) | 20 (12–33) | 18 (12–26) | 0.060 | | 28-day ICU mortality, n (%) | 28 (33.7) | 54 (39.4) | 0.398 | | Outcome, n (%) | | Discharged | 51 (61.4) | 78 (56.9) | 0.510 | | Deceased | 32 (38.6) | 59 (43.1) | |
|
|
ICU, intensive care unit; IQR, interquartile range; NA, not applicable. Bold values denote statistical significance.
|
